In the United States, the Centers for Disease Control and Prevention (CDC) reports that over 38.4 million individuals, approximately 11.6% of the population, are currently living with diabetes [2]
In recent years, GLP-1 medications have become a focal point in the medical community due to their innovative treatment mechanisms, significant therapeutic efficacy, and broad development prospects
However, its important to speak with a doctor before beginning any type of fertility treatment, as there can be potential risks and side effects associated with each method
The company claims it supports GLP-1 production, but published peer-reviewed research on RSB11 specifically is limited
It is not for human consumption, diagnostic use, or therapeutic purposes
Many Hashimoto's patients find that moderate doses (0.5-1.0 mg semaglutide, 5-10 mg tirzepatide ) provide meaningful benefits without the gastrointestinal intensity of maximum doses